..

()
, ,

,
.

,
.



.
,
,
( ),
(),
.
Gold, 2009

40
10%;
2002 . 600
; 16
,
, ;
4- (
- ,
)
200-300 .
2,74 (2000 .);
,
;
2020 . 3-
4,7 .



3.0
3.0
2.5
2.5

59%

64%

35%

+163%

7%

2.0
2.0
1.5
1.5
1.0
1.0
0.5
0.5
0.0 0

1965 - 1998 1965 - 1998 1965 - 1998 1965 - 1998 1965 - 1998
Source: NHLBI/NIH/DHHS

6


1970 2002 .

Source: Jemal A. et al. JAMA 2005

Number Deaths x 1000

:
, , 1980-2000
70
60
Men

50
40

Women
30
20
10
0
1980

1985

1990

1995

2000

Source: US Centers for Disease Control and Prevention, 2002

:


( )
-

T-

( )

( )

(
)

( -
)

Pulmonary Hypertension in COPD

Chronic hypoxia

Pulmonary vasoconstriction

Muscularization
Pulmonary hypertension

Intimal
hyperplasia
Fibrosis

Cor pulmonale

Obliteration
Edema

Death
Source: Peter J. Barnes, MD

Ep cells

CD4+ (Th2)

CD8+
(Tc1)

Ep cells

Source: Peter J. Barnes, MD

Source: Peter J. Barnes, MD


,
/
.
.

.
1/ <0,70 1
<80%
.

, x
.
,
.
.

 ,
40 -
.
,

.

( ).
.
( ).

, ,
.

. ,
.
: .

:
: ,

-
: C

1 80%
;
1/ 70% .

1 50
,

,
,

:
0

FEV1 FVC

FEV1/ FVC

4.150

5.200

80 %

2.350

3.900

60 %

FEV1

FVC

FEV1

FVC
4

200 400 g

15

500 g Turbohaler

15

160 g

45

, 1
15% 200
** Usually 8 puffs of 20 g



1 < 80%
1/ < 70%

> 400 ml

< 400 ml

30 mg
2

< 400 ml

1
> 400 ml

(, )
I:

FEV1/FVC < 70%; FEV1 > 80%

/ (, )

II:

FEV1/FVC < 70%; 50% < FEV1 < 80%

/ (, ,
)
FEV1/FVC < 70%; 30% < FEV1 < 50%
/ (, ,
)
FEV1/FVC < 70%; FEV1 < 30% FEV1 <
50%

III:

IV:

100%

35

;
;

;
;
;
;
.




,

(
).

www.goldcopd.org

(
). ,

/
.

(
).


.

b2-

2_, ,
( ).


,
( ).
2_

,
,
1 (
).


.
,

, .

,
(\)

(, )

100-200 (5)

4-6

()

100-200 (1)

4-6

25-50

12

4,5-12 (0,01)

12

20,40 (0,25-5)

6-8

18

24

200/80 (1,25\0,5)

6-8

100-600

24

2-

2-
()

()
()

()



( ):
, 1 <50%
( III IV: )

(, 3 3 )

( ),



( + 2-
)
,
( ),
www.goldcopd.org

/
( ).


50% ( ).

65 ,
65 1 <40%

( , )
( , D)

,

.

,
,
,
,
, (
),
.

 (GOLD)

0:

I:
1/
<70%
1 80%

II:
1/ <70%
50% 1 < 80%

III:
1/
<70%
30% 1
<50%

IV:
1/ <70%
1 <30% 1
<50% +

;
+
+

+
+

+

,
\

50-400

0,2-0,4

100, 200, 400,

0.2, 0,25, 0,5

50-500

100

\ ()

4,5\160, 9\320

/ ()

50\100, 250, 500

25\50, 125, 250

5-60

4, 8. 16

40

-

-

-

-

FEV1
(A)
(A)
(A)
(A)
(A)
(A)

(B)
(B)
(A)
(A)
NA
(B)

(B)
NA
(B)

(B)

(B)
NA
NA

(B)
NA

(A)
(A)
(A)
(A)
(B)
(A)

NA
(B)
(A)
(A)
(A)
(B)

NA

NA

NA

NA

NA

NA

,
,
/
,
,
.


,

(
).

(
2_
) ( ).


.
,
( ).

1 <50% .
30-40
7-10
-
,

( )

;
. ,
.
/
,
2_ ( ).
,
, .
.
, , ,
.
.
,
,
.

,
,
(
B);
,
,
(
C);
,
(
B).

37 ( D).

H. influenzae
S. pneumoniae
M. catarrhalis
Chlamydia pneumoniae

()

(K. pneumoniae,
E. coli, Proteus, Enterobacter ..)

P. aeruginosa

P. Aeruginosa

:
,
, (>3 ),

3

:
_ ()
,
/ _

_/ _
(_)

_/ _
(_)

(,
,
)

Pseudomonas:

(,
)

\ :

2_ 3_

()

_
P. urugenosa

,


(,
, )

,


,
,


,

,
,
, 1
( )


(
).

( )
,
,
( )
( )
-
,

( )

[57].

.

: , , /
().

?
GOLD
, 37
5-
, (2000/125 ) [85], [86], [69],
[33, 87], [88], [69] [90].
(35 )
,
[91, 92]. , ,

,